Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.11
GIKLY's Cash to Debt is ranked higher than
69% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.33 vs. GIKLY: 1.11 )
GIKLY' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 1.11

Equity to Asset 0.31
GIKLY's Equity to Asset is ranked higher than
53% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. GIKLY: 0.31 )
GIKLY' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.37
Current: 0.31

0.28
0.37
Interest Coverage 3.07
GIKLY's Interest Coverage is ranked higher than
50% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.28 vs. GIKLY: 3.07 )
GIKLY' s 10-Year Interest Coverage Range
Min: 1.56   Max: 18.28
Current: 3.07

1.56
18.28
F-Score: 9
Z-Score: 2.43
M-Score: -2.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 26.02
GIKLY's Operating margin (%) is ranked higher than
94% of the 306 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.14 vs. GIKLY: 26.02 )
GIKLY' s 10-Year Operating margin (%) Range
Min: 15.53   Max: 26.85
Current: 26.02

15.53
26.85
Net-margin (%) 13.04
GIKLY's Net-margin (%) is ranked higher than
86% of the 306 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.12 vs. GIKLY: 13.04 )
GIKLY' s 10-Year Net-margin (%) Range
Min: 2.8   Max: 16.2
Current: 13.04

2.8
16.2
ROE (%) 18.54
GIKLY's ROE (%) is ranked higher than
91% of the 303 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.11 vs. GIKLY: 18.54 )
GIKLY' s 10-Year ROE (%) Range
Min: 4.27   Max: 18.34
Current: 18.54

4.27
18.34
ROA (%) 6.08
GIKLY's ROA (%) is ranked higher than
79% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.67 vs. GIKLY: 6.08 )
GIKLY' s 10-Year ROA (%) Range
Min: 1.34   Max: 6.51
Current: 6.08

1.34
6.51
ROC (Joel Greenblatt) (%) 40.31
GIKLY's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.82 vs. GIKLY: 40.31 )
GIKLY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 19.07   Max: 41.62
Current: 40.31

19.07
41.62
» GIKLY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GIKLY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 29.50
GIKLY's P/E(ttm) is ranked higher than
80% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.10 vs. GIKLY: 29.50 )
GIKLY' s 10-Year P/E(ttm) Range
Min: 17.7   Max: 95
Current: 29.5

17.7
95
P/B 5.10
GIKLY's P/B is ranked higher than
61% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.06 vs. GIKLY: 5.10 )
GIKLY' s 10-Year P/B Range
Min: 3.09   Max: 6.67
Current: 5.1

3.09
6.67
P/S 3.76
GIKLY's P/S is ranked higher than
66% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.93 vs. GIKLY: 3.76 )
GIKLY' s 10-Year P/S Range
Min: 2.33   Max: 6.66
Current: 3.76

2.33
6.66
PFCF 24.35
GIKLY's PFCF is ranked higher than
89% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 220.16 vs. GIKLY: 24.35 )
GIKLY' s 10-Year PFCF Range
Min: 13.83   Max: 1434
Current: 24.35

13.83
1434
EV-to-EBIT 18.83
GIKLY's EV-to-EBIT is ranked higher than
81% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.48 vs. GIKLY: 18.83 )
GIKLY' s 10-Year EV-to-EBIT Range
Min: 14.2   Max: 68.3
Current: 18.83

14.2
68.3
PEG 1.05
GIKLY's PEG is ranked higher than
98% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. GIKLY: 1.05 )
GIKLY' s 10-Year PEG Range
Min: 0   Max: 2.2
Current: 1.05

0
2.2
Current Ratio 3.03
GIKLY's Current Ratio is ranked higher than
78% of the 305 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.75 vs. GIKLY: 3.03 )
GIKLY' s 10-Year Current Ratio Range
Min: 2.19   Max: 3.26
Current: 3.03

2.19
3.26
Quick Ratio 1.73
GIKLY's Quick Ratio is ranked higher than
71% of the 305 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.82 vs. GIKLY: 1.73 )
GIKLY' s 10-Year Quick Ratio Range
Min: 1.15   Max: 1.88
Current: 1.73

1.15
1.88

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.45
GIKLY's Dividend Yield is ranked lower than
74% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.36 vs. GIKLY: 0.45 )
GIKLY' s 10-Year Dividend Yield Range
Min: 0.38   Max: 0.6
Current: 0.45

0.38
0.6
Dividend Payout 0.12
GIKLY's Dividend Payout is ranked higher than
95% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. GIKLY: 0.12 )
GIKLY' s 10-Year Dividend Payout Range
Min: 0.19   Max: 0.59
Current: 0.12

0.19
0.59
Yield on cost (5-Year) 0.50
GIKLY's Yield on cost (5-Year) is ranked lower than
70% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.41 vs. GIKLY: 0.50 )
GIKLY' s 10-Year Yield on cost (5-Year) Range
Min: 0.38   Max: 0.6
Current: 0.5

0.38
0.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.96
GIKLY's Price/Median PS Value is ranked higher than
84% of the 323 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.13 vs. GIKLY: 0.96 )
GIKLY' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 1.43
Current: 0.96

0.63
1.43
Earnings Yield (Greenblatt) 5.30
GIKLY's Earnings Yield (Greenblatt) is ranked higher than
73% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. GIKLY: 5.30 )
GIKLY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.5   Max: 7
Current: 5.3

1.5
7

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare: » details
Traded in other countries:GRFS.USA, GRF.P.Spain, 0EM7.country, GRF.Spain, G0FB.Germany, OZT.Germany
Grifols SA was founded in 1940 in Barcelona, Spain by Dr. José Antonio Grifols i Roig. The Company was incorporated in Spain as a limited liability company on June 22, 1987 under the name Grupo Grifols, S.A., and changed its name to Grifols, S.A. in 2005. The Company is a vertically integrated producer of plasma derivatives. Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The Company 150 FDA-licensed plasma collection centers located across the United States. It has expanded its plasma collection network through a combination of organic growth and acquisitions and the opening of new plasma collection centers. In 2012, it purchased three plasma collection centers in the United States from Cangene Corporation, a Canadian biopharmaceutical firm. The Company's products and services are used by healthcare providers in approximately 100 countries to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions, and we have a direct presence, through the operation of commercial subsidiaries, in 24 countries. Its business segments arte: Bioscience, Diagnostic and Hospital. The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The Diagnostic division is engaged in researching, developing, manufacturing and marketing vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. The Hospital division manufactures and in certain instances installs products used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids, which are sold almost exclusively in Spain and Portugal.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK